Department of Immunology, Jagiellonian University Medical College, 18 Czysta Street, 31-121 Krakow, Poland.
Int J Mol Sci. 2022 Feb 4;23(3):1772. doi: 10.3390/ijms23031772.
This review article is focused on antihypertensive drugs, namely angiotensin converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB), and their immunomodulatory properties reported in hypertensive patients as well as in experimental settings involving studies on animal models and cell lines. The immune regulatory action of ACEI and ARB is mainly connected with the inhibition of proinflammatory cytokine secretion, diminished expression of adhesion molecules, and normalization of CRP concentration in the blood plasma. The topic has significant importance in future medical practice in the therapy of patients with comorbidities with underlying chronic inflammatory responses. Thus, this additional effect of immune regulatory action of ACEI and ARB may also benefit the treatment of patients with metabolic syndrome, allergies, or autoimmune disorders.
这篇综述文章主要关注降压药物,即血管紧张素转换酶抑制剂(ACEI)和血管紧张素 II 受体阻滞剂(ARB),以及它们在高血压患者以及涉及动物模型和细胞系研究的实验环境中报告的免疫调节特性。ACEI 和 ARB 的免疫调节作用主要与抑制促炎细胞因子的分泌、减少粘附分子的表达以及使血浆中 CRP 浓度正常化有关。在伴有潜在慢性炎症反应的合并症患者的治疗中,这一课题在未来的医学实践中具有重要意义。因此,ACEI 和 ARB 的免疫调节作用的这一附加效果也可能有益于治疗代谢综合征、过敏或自身免疫性疾病的患者。